Last reviewed · How we verify
Afobazole
At a glance
| Generic name | Afobazole |
|---|---|
| Also known as | Fabomotizole |
| Sponsor | Valenta Pharm JSC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders (PHASE4)
- A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afobazole CI brief — competitive landscape report
- Afobazole updates RSS · CI watch RSS
- Valenta Pharm JSC portfolio CI